AMAL Therapeutics is a Swiss biotech developing therapeutic vaccines, and aiming at overcoming the challenges around effective anti-cancer therapy by stimulating the immune system in a unique way, to create immunological memory.
AMAL joined the Boehringer Ingelheim group of companies in 2019.

Products, services, technology

KISIMA®, a novel peptide/protein-based immunisation technology platform, enables the assembly within one chimeric fusion protein of 3 elements essential to generate potent immunity.

Location

Avenue de la Roseraie 64, 1205 Genève, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2012

  • Number of employees in Switzerland

    10-19

Key business